SignaBlok to present novel approach to preventing cancer recurrence at the 2026 American Association for Cancer Research (AACR) annual meeting
SignaBlok to present favorable preclinical data on a first-in-class TREM-1 therapy for retinopathy of prematurity (ROP) at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting
SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of sepsis, pulmonary inflammation and fibrosis at the 2025 Respiratory Innovation Summit (RIS) and American Thoracic Society (ATS) International Conference
SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SignaBlok presented preclinical data on the use of ligand-independent TREM-1 blockers as innate immune checkpoint inhibitors to overcome cancer immunotherapy resistance at the CICON23
SignaBlok attended the COVID-19 Virtual Partnering event and presented company’s approach to treatment of acute respiratory distress syndrome (ARDS), a major complication in severe cases of COVID-19
SignaBlok pitched on company’s standalone and combination immuno-oncology therapy at the 2019 Life Sciences Summit
SignaBlok selected as a RESI Pitch Challenge finalist to pitch on company’s oncology program at the 2019 Redefining Early Stage Investments (RESI) Conference
SignaBlok presented data on preclinical antitumor activity of a first-in-class TREM-1 inhibitory peptide GF9 as monotherapy and in combo with chemotherapy or radiation at the 2019 AACR Annual Meeting
SignaBlok presented preclinical data supporting efficacy of ligand-independent TREM-1 inhibitor in ameliorating alcoholic liver disease at the Liver Meeting 2018: American Association for the Study of Liver Diseases (AASLD)
